Navigation Links
Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
Date:1/7/2014

>Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

  1. Giugliano, R et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013;369:2093-2104.
  2. Buller, H et al. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 2013;369:1406-1415.
  3. Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol 2010;50:743-753.
  4. Daiichi
    '/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
2. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
3. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
4. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
5. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
6. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
7. Orexigen Resubmits Contrave New Drug Application
8. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
9. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
10. Omeros Submits New Drug Application to U.S. FDA for OMS302
11. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... PARIS , Sept. 30, 2014 ... and NYSE: SNY) today announced that a Phase 2a ... IL-4 and IL-13 signaling, met all primary and secondary ... polyps (CSwNP) who did not respond to intranasal corticosteroids. ... dupilumab for use in the treatment of another allergic ...
(Date:9/29/2014)... PHILADELPHIA , Sept. 29, 2014  Repeated exposure ... life is associated with early childhood obesity, say researchers ... in a retrospective study based on data from ... The researchers found that children with ... infancy were particularly more likely to be at risk ...
(Date:9/29/2014)... DIEGO , 29 septembre 2014 ... (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ont ... fusion définitif en vertu duquel Daiichi Sankyo fera ... circulation d,Ambit Biosciences à 15 dollars par action ... d,achat qui sera suivie d,une fusion avec une ...
Breaking Medicine Technology:Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... AUSTIN, Texas, May 24, 2011 A paper published ... demonstrated that adding OVA1 to a physician,s preoperative ... ovarian cancers than a physician,s preoperative assessment alone. The ... the journal, which is the official publication of the ...
... Holdings, Inc. (OTCQB: ABHI), a leader in the development of ... has signed a new line of credit with East West ... to expire July 2011. The new line of credit expands ... the previous revolving line and extends the line by one ...
Cached Medicine Technology:OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 2OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 3OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment 4AmbiCom Renews and Expands Line of Credit With East West Bank 2AmbiCom Renews and Expands Line of Credit With East West Bank 3
(Date:9/29/2014)... Every autumn, as high school and ... running season takes off! Athletes typically train throughout the ... season. Zensah®, the leading compression apparel company, makes the ... socks for cross country running. , The ... delayed onset muscle soreness (DOMS) throughout training in addition ...
(Date:9/29/2014)... International Alliance for Fitness Professionals ... with a certification program that gives trainees the ... own lives, and the lives of others. The ... community at large, through innovative certification program designs, ... practice of fitness, wellness, nutrition, health, and physical ...
(Date:9/29/2014)... 30, 2014 (PRWEB) September 29, 2014 ... smartphones, tablets and laptops provides the delivery of training, ... from youth to adult, to raise and enhance one’s ... licensure, or to obtain certification in your chosen field. ... workforce to compete effectively and at MMU we make ...
(Date:9/29/2014)... Franklin, TN (PRWEB) September 29, 2014 ... visits are attributed to complaints of dizziness and imbalance. ... person to the next and the population range can ... ages many more people will be seeking medical assistance ... complaints. Soldiers returning from combat with post blast or ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 Sleep deprivation ... get lucky when there little one can slumber soundly from ... consistent naps each day. For many parents, the perfect sleeping ... you're exhausted and consumed with stress. After Felicia brought ... that like other babies she would fall asleep without much ...
Breaking Medicine News(10 mins):Health News:Muscle Support and Style With New Compression Leg Sleeves For Cross Country Runners 2Health News:Narconon Louisiana New Life Retreat Announces Stephen Mogavero Now Certified as a Personal Trainer 2Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 2Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 3Health News:North American Seminars Received PT Continuing Education Course Approval in California and Nevada and Illinois for an Online Vestibular Continuing Education Course 2Health News:Mommy Blogger Offers Advice on Getting Your Baby to Sleep 2Health News:Mommy Blogger Offers Advice on Getting Your Baby to Sleep 3
... in circuits that regulate serotonin in certain parts of the ... cocaine-seeking, based on mouse studies published online this week in ... "The impetus for this research was our interest in ... in ways that lead to mood changes, depression, anxiety, and ...
... cuts conception rate, study found , THURSDAY, Oct. 29 ... minutes after being artificially inseminated greatly boost their odds ... treated for subfertility with IUI [intrauterine insemination] to remain ... chance at conceiving," said Inge Custers, lead author of ...
... ... Me Not Flower Club ("FMN-FC") today announced the launch of its online floral gift ... as well as other diseases associated with aging. , ... Camarillo, California (PRWEB) October 30, 2009 -- In ...
... expert offers tips for those thrown off schedule by Daylight ... That extra hour of sleep you,ll get in most parts ... the beginning of Daylight Saving Time could spell trouble for ... Atul Malhotra, medical director of the sleep disorders research program ...
... expectant moms led to bigger, healthier infants, studies show ... women head the list of people who should get ... new studies highlight the benefits of vaccination for moms-to-be ... births and reduced rates of hospitalization top the findings, ...
... , VIRGINIA BEACH, Va., Oct. 30, 2009 AMERIGROUP Corporation (NYSE: ... quarter of 2009 was $22.5 million, or $0.43 per diluted share, ... quarter of 2008. Third quarter earnings are in line with ... October 26, 2009, and reflect elevated medical costs associated ...
Cached Medicine News:Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 2Health News:Stress-induced changes in brain circuitry linked to cocaine relapse 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 2Health News:Forget-Me-Not-Flower-Club Launches Floral Gift Program For Caregivers: Alzheimer's Awareness Month Program Offers Resources, Recognition for Friends and Family 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: